Oral administration of silicon-based agents attenuates renal fibrosis

Area of Science:

• Nephrology
• Biochemistry
• Pharmacology

Background:

• Renal fibrosis is a hallmark of chronic kidney disease progression.
• Oxidative stress significantly exacerbates renal fibrosis.
• Silicon-based agents are known to increase hydrogen production and reduce oxidative stress.

Purpose of the Study:

• To evaluate the efficacy of oral silicon-based agents in mitigating renal fibrosis.
• To investigate the underlying mechanisms by which silicon-based agents exert their effects.
• To explore the impact on oxidative stress, apoptosis, and fibrotic pathways.

Main Methods:

• A unilateral ureteral obstruction mouse model was utilized.
• Mice were treated with silicon-based agents and compared to control groups.
• Analyses included histological assessment, RNA sequencing, and immunohistochemistry on postoperative days 1 and 14.
• Key markers assessed were renal fibrosis, tubular cell apoptosis, transforming growth factor-β, 4-hydroxy-2-nonenal, and complement component 3.

Main Results:

• Silicon-based agent treatment significantly reduced renal fibrosis, tubular cell apoptosis, and expression of transforming growth factor-β and 4-hydroxy-2-nonenal.
• RNA sequencing revealed downregulation of fibrosis-associated pathways in treated mice.
• Complement component 3 expression and activity were significantly inhibited early post-operation.

Conclusions:

• Oral silicon-based agents demonstrate significant therapeutic potential against renal fibrosis.
• These agents suppress oxidative stress, tubular cell death, and pro-fibrotic factors.
• Inhibition of complement component 3 appears to be an early mechanism of action.